Sigma-Aldrich has announced the establishment of a worldwide RNAi Partnership Program with select academic institutions to advance functional genomics research.
Scientists from participating organizations will benefit from unique access to a broad portfolio of intellectual property, early access to emerging technologies, and special partnership pricing on Sigma's range of functional genomics and RNAi products.
As part of the program, researchers at participating institutions will have early access to technologies that are developed through Sigma-Aldrich's collaborations with TRC, Oxford BioMedica and Benitec.
The partnership program will also facilitate collaborations with scientists at Sigma-Aldrich to validate current and emerging RNAi technologies.
Program participants will also benefit from a dedicated support team on Sigma's functional genomics product portfolio.
This extensive product offering includes the Lentivirus-based MISSION™ TRC shRNA libraries, targeting 15,000 human and mouse genes, activated lentiviral particles, custom siRNA, and qPCR reagents.
"The RNAi Partnership Program provides researchers with cutting-edge products in functional genomics, access to key RNAi-related intellectual property, and dedicated technical support," said Keith Jolliff, Director of Strategic Marketing.
"Our aim is to accelerate the rate at which the scientific community is able to utilize emerging RNAi technologies in order to facilitate innovative approaches that create advances in both fundamental and applied life science research."
Dr. Andrew I. Brooks, Director of the Bionomics Research and Technologies Core (BRTC) said, "The BRTC provides high technology expertise and high-throughput analysis using state-of-the-art platforms."
"Sigma-Aldrich has established itself as a leader in the area of RNAi, and I am pleased that we are a part of the RNAi Partnership Program."
"The benefits this membership brings are substantial, and the tools and services that Sigma-Aldrich offers are invaluable to any institution that works with RNAi technologies."